Your browser doesn't support javascript.
loading
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes.
Egeberg, Alexander; Merola, Joseph F; Schäkel, Knut; Puig, Luis; Mahar, Patrick D; Wang, Isabella Yali; Pavo, Imre; Schuster, Christopher; Griffiths, Christopher E M.
Afiliação
  • Egeberg A; Bispebjerg and Frederiksberg Hospital, Copenhagen University, Copenhagen, Denmark.
  • Merola JF; Division of Rheumatology, Department of Dermatology and Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States.
  • Schäkel K; Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Puig L; Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Mahar PD; Eli Lilly and Company, Indianapolis, IN, United States.
  • Wang IY; Department of Dermatology, Royal Children's Hospital, Faculty of Medicine, Nursing and Health Sciences, Skin Health Institute, The University of Melbourne, Melbourne, VIC, Australia.
  • Pavo I; Eli Lilly and Company, Indianapolis, IN, United States.
  • Schuster C; Eli Lilly and Company, Indianapolis, IN, United States.
  • Griffiths CEM; Eli Lilly and Company, Indianapolis, IN, United States.
Front Med (Lausanne) ; 10: 1171132, 2023.
Article em En | MEDLINE | ID: mdl-36974067
[This corrects the article DOI: 10.3389/fmed.2022.1092688.].
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Dinamarca
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Dinamarca